Vivos Therapeutics (VVOS) EBIT Margin (2020 - 2026)
Vivos Therapeutics (VVOS) reported EBIT Margin of 128.67% for Q1 2026, up 124.0% year-over-year from 57.44% in Q1 2025, and up 22.9% quarter-over-quarter from 166.89% in Q4 2025.
Vivos Therapeutics (VVOS) EBIT Margin (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of EBIT Margin data on file, last reported at 128.67% in Q1 2026.
- EBIT Margin for Q1 2026 came in at 128.67%, up 124.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 115.47% (down 3819.0% YoY), and the FY2025 annual result was 114.05%, down 3973.0% from the prior year.
- EBIT Margin grew to 128.67% in Q1 2026 per VVOS's latest filing, from 166.89% in the prior quarter.
- Over five years, EBIT Margin peaked at 47.76% in Q2 2024 and troughed at 182.19% in Q1 2022.
- A 5-year average of 120.9% and a median of 127.36% in 2025 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2022 and 2024: EBIT Margin slumped 35172 bps in 2022, then surged 8529 bps in 2024.
- A 5-year view of EBIT Margin shows it stood at 153.49% in 2022, then gained by 17 bps to 127.25% in 2023, then jumped by 40 bps to 75.88% in 2024, then sank by 120 bps to 166.89% in 2025, then grew by 23 bps to 128.67% in 2026.
- Business Quant data shows VVOS's EBIT Margin at 128.67% in Q1 2026, 166.89% in Q4 2025, and 69.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.17% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 19.94% |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | -128.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.67% |
| Dec 31, 2025 | -166.89% |
| Sep 30, 2025 | -69.79% |
| Jun 30, 2025 | -127.36% |
| Mar 31, 2025 | -129.91% |
| Dec 31, 2024 | -75.88% |
| Sep 30, 2024 | -68.52% |
| Jun 30, 2024 | -47.76% |
| Mar 31, 2024 | -110.70% |
| Dec 31, 2023 | -127.25% |
| Sep 30, 2023 | -110.27% |
| Jun 30, 2023 | -133.05% |
| Mar 31, 2023 | -129.76% |
| Dec 31, 2022 | -153.49% |
| Sep 30, 2022 | -127.34% |
| Jun 30, 2022 | -166.44% |
| Mar 31, 2022 | -182.19% |
| Dec 31, 2021 | 198.22% |
| Sep 30, 2021 | -121.05% |
| Jun 30, 2021 | -90.30% |